Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 3/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084562 | 0.85 | SYK (0.76) | SYKFPR2PROKR1TTRRBP4 | |
| SCHEMBL272940 | 0.84 | SYK (0.49) | SYKKDM4EMAPTLMNANPSR1 | |
| SCHEMBL13419182 | 0.84 | SYK (0.74) | SYKFPR2PROKR1TTRRBP4 | |
| SCHEMBL17708375 | 0.82 | SYK (0.67) | SYKFPR2PROKR1TTRRBP4 | |
| SCHEMBL2691167 | 0.81 | HRH3 (0.57) | SYKKDM4EMAPTLMNANPSR1 | |
| SCHEMBL28237073 | 0.81 | KDM4E (0.47) | SYKKDM4EMAPTLMNANPSR1 | |
| SCHEMBL10195706 | 0.81 | SYK (1.00) | SYKFPR2PROKR1 | |
| SCHEMBL14453573 | 0.81 | SYK (0.70) | SYKFPR2PROKR1HTR2CHTR2B | |
| SCHEMBL10196595 | 0.81 | ACHE (0.52) | SYKFPR2PROKR1HTR2CHTR2B | |
| SCHEMBL9921755 | 0.81 | HTR2C (0.53) | SYKFPR2PROKR1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | SYK 53/4885KDM4E 1104/4885MAPT 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.